Clinical Trials Logo

Hepatic Transplantation clinical trials

View clinical trials related to Hepatic Transplantation.

Filter by:
  • None
  • Page 1

NCT ID: NCT05047406 Active, not recruiting - Clinical trials for Transplantation Infection

Bacillus Clausii in Liver Transplantation

Start date: September 7, 2021
Phase: Phase 2
Study type: Interventional

A prospective, randomized, controlled study of the safety and efficacy of using Bacillus clausii probiotic oral preparation to decrease the incidence of infection during the first 30 days after living donor liver transplantation surgery.

NCT ID: NCT03174327 Completed - Clinical trials for Hepatic Transplantation

Evaluation of Hepatic Rigidity by Ultrasonic Impulse Elastography in Liver Transplant Patients

SUPERSONIC
Start date: June 27, 2017
Phase: N/A
Study type: Interventional

Interventional study with minimal risks and constraints, prospective, mono-centric.

NCT ID: NCT02853981 Completed - Clinical trials for Hepatic Transplantation

Clamp-crush Technique Versus Harmonic Scalpel in Living Donor Hepatectomy

KK_HS
Start date: January 2015
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to determine whether clamp-crush technique for liver parenchymal transection is as safe as Harmonic scalpel device. outcomes will include: perioperative mortality, surgery-related complications, blood loss, amount of blood loss during hepatectomy, operating time, transection speed, markers of liver parenchymal injury and hospital stay.

NCT ID: NCT01388387 Completed - Clinical trials for Hepatic Transplantation

Pharmacogenetic Study of Tacrolimus in Hepatic Transplant (CYPTAC'H)

Start date: February 22, 2012
Phase: N/A
Study type: Interventional

The choice of an immunosuppressant after hepatic transplant is now more difficult than before because of the increasing number of drugs available. Pharmacokinetic, pharmacodynamic and pharmacogenetic information can help to choose the best treatment and the best dose for each patient. The genetic polymorphism of enzymes metabolizing treatments can affect their efficacy and safety. Concerning tacrolimus, CYP3A5 activity is a major determinant of the dose needed to reach target concentrations. This study is aimed at evaluating the impact of both donor and recipient CYP3A5 genetic polymorphisms on tacrolimus exposure in patients with hepatic transplant.